Thermogenesis and related metabolic targets in anti-diabetic therapy

Handbook of Experimental Pharmacology

Volumn 203, Issue , 2011, Pages 201-255

  Arch, Jonathan R S ^a  

^a UNIVERSITY OF BUCKINGHAM   (United Kingdom)

Author keywords

Drug discovery; Exercise; Fatty acid oxidation; Insulin sensitivity; Thermogenesis

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; ADIPONECTIN; ALPHA2 GLYCOPROTEIN; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CILIARY NEUROTROPHIC FACTOR RECEPTOR; DIACYLGLYCEROL ACYLTRANSFERASE; EXENDIN 4; FATTY ACID SYNTHASE; FIBROBLAST GROWTH FACTOR 21; GHRELIN; GLITAZONE DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN; LIRAGLUTIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; SIRTUIN 1; THYROID HORMONE; UNINDEXED DRUG; VILDAGLIPTIN; ZINC; ANTIOBESITY AGENT; HORMONE;

ADRENERGIC SYSTEM; CALORIC RESTRICTION; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG TARGETING; ENERGY EXPENDITURE; HUMAN; KINESIOTHERAPY; LIPID METABOLISM; LIPID OXIDATION; METABOLIC SYNDROME X; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; THERMOGENESIS; ANIMAL; DIABETES MELLITUS; DRUG DESIGN; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTI-OBESITY AGENTS; DIABETES MELLITUS; DRUG DESIGN; EXERCISE THERAPY; HORMONES; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; THERMOGENESIS;

EID: 79955627418     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-17214-4_10     Document Type: Review

References (385)

1. Abdul-Ghani MA, DeFronzo RA (2008) Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Curr Diab Rep 8:173-178
2. Abu-Elheiga L, Oh W, Kordari P, Wakil SJ (2003) Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. Proc Natl Acad Sci USA 100:10207-10212 (Pubitemid 37071857)
3. Abu-Elheiga L, Matzuk MM, Kordari P, Oh W, Shaikenov T, Gu Z, Wakil SJ (2005) Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci USA 102:12011-12016 (Pubitemid 41291120)
4. Addy C, Wright H, Van Laere K, Gantz I, Erondu N,Musser BJ, Lu K, Yuan J, Sanabria-Bohorquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN 3rd, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depre M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ,Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB (2008) The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78
5. Aja S, Landree LE, Kleman AM, Medghalchi SM, Vadlamudi A, McFadden JM, Aplasca A, Hyun J, Plummer E, Daniels K, Kemm M, Townsend CA, Thupari JN, Kuhajda FP, Moran TH, Ronnett GV (2008) Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight. Am J Physiol Regul Integr Comp Physiol 294:R352-R361 (Pubitemid 351213738)
6. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640-1645
7. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen LB (2003) Selective inhibition of 11 β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755-4762 (Pubitemid 37378389)
8. Allen TL, Matthews VB, Febbraio MB (2011) Overcoming insulin resistance with ciliary neurotrophic factor. Handb Exp Pharmacol. doi:10.1007/978-3-642- 17214-4-9
9. Almeda-Valdes P, Cuevas-Ramos D, Mehta R, Gomez-Perez FJ, Cruz-Bautista I, Arellano-Campos O, Navarrete-Lopez M, Aguilar-Salinas CA (2010) Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance. Cardiovasc Diabetol 9:26
10. ALS (1996) A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46:1244-1249
11. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, Pillot B, Bado A, Tronche F, Mithieux G, Vaulont S, Burcelin R, Viollet B (2006) Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147:2432-2441
12. Araya AV, Orellana X, Espinoza J (2008) Evaluation of the effect of caloric restriction on serum BDNF in overweight and obese subjects: preliminary evidences. Endocrine 33:300-304
13. 3-adrenoreceptor. Taylor and Francis, London, pp 48-76
14. 3-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 440:99-107
15. Arch JRS (2007) Comment on: Schmidt MI, Duncan BB, Vigo A et al. (2006) Leptin and incident type 2 diabetes: risk or protection? Diabetologia 50:239-240
16. Arch JR (2008) The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 378:225-240
17. Arch JR, Ainsworth AT (1983) Thermogenic and antiobesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr 38:549-558 (Pubitemid 13010200)
18. Arch JRS, Ainsworth AT, Ellis RDM, Piercy V, Thody VE, Thurlby PL, Wilson C, Wilson S, Young P (1984) Treatment of obesity with thermogenic β-adrenoceptor agonists: studies on BRL 26830A in rodents. Int J Obes 8(Suppl 1):1-11 (Pubitemid 15019725)
19. Arch JR, Hislop D, Wang SJY, Speakman JR (2006) Some mathematical and technical issues in the measurement and interpretation of open-circuit indirect calorimetry in small animals. Int J Obes 30:1322-1331 (Pubitemid 44306513)
20. Asensio CD, Arsenijevic D, Lehr D, Giacobino J-P, Muzzin P, Rohner-Jeanrenaud F (2008) Effects of leptin on energy metabolism in β-less mice. Int J Obes 32(6):936-942 (Pubitemid 351986218)
21. Assah FK, Brage S, Ekelund U, Wareham NJ (2008) The association of intensity and overall level of physical activity energy expenditure with a marker of insulin resistance. Diabetologia 51:1399-1407
22. Avignon A, Lapinski H, Rabasa-Lhoret R, Caubel C, Boniface H, Monnier L (2000) Energy metabolism and substrates oxidative patterns in type 2 diabetic patients treated with sulphonylurea alone or in combination with metformin. Diabetes Obes Metab 2:229-235 (Pubitemid 33072191)
23. Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, Kern PA, Ranganathan G (2009) Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab 296:E480-E489
24. Banks WA (2008) The blood-brain barrier as a cause of obesity. Curr Pharm Des 14:1606-1614
25. Banks AS, Kon N, Knight C, Matsumoto M, Gutierrez-Juarez R, Rossetti L, Gu W, Accili D (2008) SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8:333-341
26. Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P (2005) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579:41-47 (Pubitemid 40023371)
27. Barwell ND, Malkova D, Moran CN, Cleland SJ, Packard CJ, Zammit VA, Gill JM (2008) Exercise training has greater effects on insulin sensitivity in daughters of patients with type 2 diabetes than in women with no family history of diabetes. Diabetologia 51:1912-1919
28. Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA (2008) Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes 57:24-31
29. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, Rudd MA, Bukoski RD, Kunos G (2004) Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110:1996-2002 (Pubitemid 39331913)
30. Baxter JD, Webb P (2009) Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 8:308-320
31. Bebernitz GR, Schuster HF (2002) The impact of fatty acid oxidation on energy utilization: targets and therapy. Curr Pharm Des 8:1199-1227 (Pubitemid 34594251)
32. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8:235-253
33. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914 (Pubitemid 36368998)
34. Benton CR, Holloway GP, Campbell SE, Yoshida Y, Tandon NN, Glatz JF, Luiken JJ, Spriet LL, BonenA(2008) Rosiglitazone increases fatty acid oxidation and fatty acid translocase (FAT/CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondria. J Physiol 586:1755-1766
35. Benziane B, Bjornholm M, Lantier L, Viollet B, Zierath JR, Chibalin AV (2009) AMP-activated protein kinase activator A-769662 is an inhibitor of the Na(+)-K(+)-ATPase. Am J Physiol Cell Physiol 297:C1554-C1566
36. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F (2010) The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 95:375-382
37. Berthiaume M, Laplante M, Festuccia W, Gelinas Y, Poulin S, Lalonde J, Joanisse DR, Thieringer R, Deshaies Y (2007) Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 148:2391-2397 (Pubitemid 46997032)
38. Billin AN (2008) PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin Invest Drugs 17:1465-1471
39. Binczek E, Jenke B, Holz B, Gunter RH, Thevis M, Stoffel W (2007) Obesity resistance of the stearoyl-CoA desaturase-deficient (scd1-/-) mouse results from disruption of the epidermal lipid barrier and adaptive thermoregulation. Biol Chem 388:405-418 (Pubitemid 46514691)
40. Birch AM, Buckett LK, Turnbull AV (2010) DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Dev 13:489-496
41. Bjursell M, Ahnmark A, Bohlooly YM, William-Olsson L, Rhedin M, Peng XR, Ploj K, Gerdin AK, Arnerup G, Elmgren A, Berg AL, Oscarsson J, Linden D (2007) Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 56:583-593 (Pubitemid 46348449)
42. Bluher S, Moschos S, Bullen J Jr, Kokkotou E, Maratos-Flier E, Wiegand SJ, Sleeman MW, Mantzoros CS (2004) Ciliary neurotrophic factorAx15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice. Diabetes 53:2787-2796 (Pubitemid 39425903)
43. Bo S, Ciccone G, Guidi S, Gambino R, Durazzo M, Gentile L, Cassader M, Cavallo-Perin P, Pagano G (2008) Diet or exercise: what is more effective in preventing or reducing metabolic alterations? Eur J Endocrinol 159(6):685-691
44. Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J (2009) Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 94:846-852
45. Bradley RL, Jeon JY, Liu FF, Maratos-Flier E (2008) Voluntary exercise improves insulin sensitivity and adipose tissue inflammation in diet-induced obese mice. Am J Physiol Endocrinol Metab 295:E586-E594
46. Braun B, Eze P, Stephens BR, Hagobian TA, Sharoff CG, Chipkin SR, Goldstein B (2008) Impact of metformin on peak aerobic capacity. Appl Physiol Nutr Metab 33:61-67
47. Bray GA (2000) Reciprocal relation of food intake and sympathetic activity: experimental observations and clinical implications. Int J Obes 24(suppl 2):S8-S17
48. Breen DM, Sanli T, Giacca A, Tsiani E (2008) Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun 374:117-122
49. Brown JM, Rudel LL (2010) Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. Curr Opin Lipidol 21:192-197
50. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W, Furnsinn C (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53:1052-1059
51. Bryzgalova G, Effendic S, Khan A, Rehnmark S, Barbounis P, Boulet J, Dong G, Singh R, Shapses S, Malm J, Webb P, Baxter JD, Grover GJ (2008) Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol 111:262-267
52. Buchanan TA (2007) (How) can we prevent type 2 diabetes? Diabetes 56:1502-1507
53. Budohoski L, Challiss RA, Cooney GJ, McManus B, Newsholme EA (1984) Reversal of dietary-induced insulin resistance in muscle of the rat by adenosine deaminase and an adenosinereceptor antagonist. Biochem J 224:327-330 (Pubitemid 15189016)
54. Buemann B, Sorensen TI, Pedersen O, Black E, Holst C, Toubro S, Echwald S, Holst JJ, Rasmussen C, Astrup A (2005) Lower-body fat mass as an independent marker of insulin sensitivity - the role of adiponectin. Int J Obes (Lond) 29:624-631 (Pubitemid 40769484)
55. Burns N, Finucane FM, Hatunic M, Gilman M, Murphy M, Gasparro D, Mari A, Gastaldelli A, Nolan JJ (2007) Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia 50:1500-1508 (Pubitemid 46878998)
56. Busch AK, Gurisik E, Cordery DV, Sudlow M, Denyer GS, Laybutt DR, Hughes WE, Biden TJ (2005) Increased fatty acid desaturation and enhanced expression of stearoyl coenzyme A desaturase protects pancreatic beta-cells from lipoapoptosis. Diabetes 54:2917-2924 (Pubitemid 41401087)
57. Butler AA, Kozak LP (2010) A recurring problem with the analysis of energy expenditure in genetic models expressing lean and obese phenotypes. Diabetes 59:323-329
58. Camacho RC, Pencek RR, Lacy DB, James FD, Donahue EP, Wasserman DH (2005) Portal venous 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion overcomes hyperinsulinemic suppression of endogenous glucose output. Diabetes 54:373-382
59. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458:1056-1060
60. Castillo M, Freitas BC, Rosene ML, Drigo RA, Grozovsky R, Maciel RM, Patti ME, Ribeiro MO, Bianco AC (2010) Impaired metabolic effects of a thyroid hormone receptor beta-selective agonist in a mouse model of diet-induced obesity. Thyroid 20:545-553
61. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA (2007) Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 267:63-69
62. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC (1994) Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17:961-969 (Pubitemid 24268605)
63. Chaston TB, Dixon JB (2008) Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes (Lond) 32:619-628 (Pubitemid 351536009)
64. Chen HC, Farese RV Jr (2005) Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol 25:482-486 (Pubitemid 40330925)
65. Chen HC, Smith SJ, Ladha Z, Jensen DR, Ferreira LD, Pulawa LK, McGuire JG, Pitas RE, Eckel RH, Farese RV Jr (2002a) Increased insulin and leptin sensitivity in mice lacking acyl CoA: diacylglycerol acyltransferase 1. J Clin Invest 109:1049-1055 (Pubitemid 34413589)
66. Chen HC, Stone SJ, Zhou P, Buhman KK, Farese RV Jr (2002b) Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue. Diabetes 51:3189-3195 (Pubitemid 35246964)
67. Chen HC, Ladha Z, Smith SJ, Farese RV Jr (2003) Analysis of energy expenditure at different ambient temperatures in mice lacking DGAT1. Am J Physiol Endocrinol Metab 284:E213-E218 (Pubitemid 36076239)
68. Chen N, Liu L, Zhang Y, Ginsberg HN, Yu YH (2005) Whole-body insulin resistance in the absence of obesity in FVB mice with overexpression of Dgat1 in adipose tissue. Diabetes 54:3379-3386 (Pubitemid 43334326)
69. Choi CS, Savage DB, Abu-Elheiga L, Liu ZX, Kim S, Kulkarni A, Distefano A, Hwang YJ, Reznick RM, Codella R, Zhang D, Cline GW, Wakil SJ, Shulman GI (2007) Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci USA 104:16480-16485 (Pubitemid 350211044)
70. Choi YH, Li C, Hartzell DL, Little DE, Della-Fera MA, Baile CA (2008) ICV leptin effects on spontaneous physical activity and feeding behavior in rats. Behav Brain Res 188:100-108
71. Chong PK, Jung RT, Rennie MJ, Scrimgeour CM (1995) Energy expenditure in type 2 diabetic patients on metformin and sulphonylurea therapy. Diabet Med 12:401-408
72. Chong AY, Lupsa BC, Cochran EK, Gorden P (2010) Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53:27-35
73. Clapham JC, Arch JRS, Tadayyon M (2001) Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 89:81-121 (Pubitemid 32367885)
74. Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, Lutz B, Zimmer A, Parker LA, Makriyannis A, Sharkey KA (2010) A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 161:629-642
75. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM (2002) Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297:240-243 (Pubitemid 34761283)
76. Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA (2009) Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia 52:723-732
77. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R, Zhao G, Marsh K, Kym P, Jung P, Camp HS, Frevert E (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3:403-416 (Pubitemid 43811782)
78. Corbett JW (2009) Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008. Expert Opin Ther Pat 19:943-956
79. Corbett JW, Harwood JH Jr (2007) Inhibitors of mammalian acetyl-CoA carboxylase. Recent Pat Cardiovasc Drug Discov 2:162-180 (Pubitemid 350200285)
80. Cox KL, Burke V, Morton AR, Beilin LJ, Puddey IB (2004) Independent and additive effects of energy restriction and exercise on glucose and insulin concentrations in sedentary overweight men. Am J Clin Nutr 80:308-316 (Pubitemid 41080003)
81. Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163-172
82. Crunkhorn S, Patti ME (2008) Links between thyroid hormone action, oxidative metabolism, and diabetes risk? Thyroid 18:227-237
83. Cui MX, Jiang JF, Zheng RL, Li RL, Wang L, Li WG, Gao MT, Yang LN, Dou JY, Wu YJ (2010) Therapeutic effects of a recombinant mutant of the human ciliary neurotrophic factor in a mouse model of metabolic syndrome. Pharmazie 65:279-283
84. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360:1509-1517
85. Dahlman I, Kaaman M, Olsson T, Tan GD, Bickerton AS, Wahlen K, Andersson J, Nordstrom EA, Blomqvist L, Sjogren A, Forsgren M, Attersand A, Arner P (2005) A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. J Clin Endocrinol Metab 90:5834-5840 (Pubitemid 41415500)
86. Darimont C, Turini M, Epitaux M, Zbinden I, Richelle M, Montell E, Ferrer-Martinez A, Mace K (2004) b3-adrenoceptor agonist prevents alterations of muscle diacylglycerol and adipose tissue phospholipids induced by a cafeteria diet. Nutr Metab (Lond) 1:4
87. Daval M, Foufelle F, Ferre P (2006) Functions of AMP-activated protein kinase in adipose tissue. J Physiol 574:55-62 (Pubitemid 43905796)
88. Derave W, Hespel P (1999) Role of adenosine in regulating glucose uptake during contractions and hypoxia in rat skeletal muscle. J Physiol 515(Pt 1):255-263 (Pubitemid 29092638)
89. Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134 (Pubitemid 41653104)
90. Dobrzyn P, Dobrzyn A, Miyazaki M, Cohen P, Asilmaz E, Hardie DG, Friedman JM, Ntambi JM (2004) Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMPactivated protein kinase in liver. Proc Natl Acad Sci USA 101:6409-6414 (Pubitemid 38585987)
91. Dobrzyn A, Dobrzyn P, Lee SH, Miyazaki M, Cohen P, Asilmaz E, Hardie DG, Friedman JM, Ntambi JM (2005) Stearoyl-CoA desaturase-1 deficiency reduces ceramide synthesis by downregulating serine palmitoyltransferase and increasing beta-oxidation in skeletal muscle. Am J Physiol Endocrinol Metab 288:E599-E607 (Pubitemid 40250556)
92. Doring H, Schwarzer K, Nuesslein-Hildesheim B, Schmidt I (1998) Leptin selectively increases energy expenditure of food-restricted lean mice. Int J Obes Relat Metab Disord 22:83-88 (Pubitemid 28058759)
93. Duncan GE (2006) Exercise, fitness, and cardiovascular disease risk in type 2 diabetes and the metabolic syndrome. Curr Diab Rep 6:29-35
94. Dzamko N, Schertzer JD, Ryall JG, Steel R, Macaulay SL, Wee S, Chen ZP, Michell BJ, Oakhill JS, Watt MJ, Jorgensen SB, Lynch GS, Kemp BE, Steinberg GR (2008) AMPK-independent pathways regulate skeletal muscle fatty acid oxidation. J Physiol 586:5819-5831
95. Eaton RP, Steinberg D, Thompson RH(1965) Relationship between free fatty acid turnover and total body oxygen consumption in the euthyroid and hyperthyroid states. J Clin Invest 44:247-260
96. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR (2001) Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161
97. Elisha B, Ziai S, Karelis AD, Rakel A, Coderre L, Imbeault P, Rabasa-Lhoret R (2010) Similar associations of total adiponectin and high molecular weight adiponectin with cardio-metabolic risk factors in a population of overweight and obese postmenopausal women: a MONET study. Horm Metab Res 42(8):590-594
98. Erion DM, Yonemitsu S, Nie Y, Nagai Y, Gillum MP, Hsiao JJ, Iwasaki T, Stark R, Weismann D, Yu XX, Murray SF, Bhanot S, Monia BP, Horvath TL, Gao Q, Samuel VT, Shulman GI (2009) SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci USA 106:11288-11293
99. Esler WP, Rudolph J, Claus TH, Tang W, Barucci N, Brown SE, Bullock W, Daly M, Decarr L, Li Y, Milardo L, Molstad D, Zhu J, Gardell SJ, Livingston JN, Sweet LJ (2007) Smallmolecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 148:5175-5185 (Pubitemid 350012622)
100. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP (2003) Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, doseranging study. JAMA 289:1826-1832 (Pubitemid 37430253)
101. Faiola B, Falls JG, Peterson RA, Bordelon NR, Brodie TA, Cummings CA, Romach EH, Miller RT (2008) PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. Toxicol Sci 105:384-394
102. Farooqi IS, O'Rahilly S (2004) Monogenic human obesity syndromes. Recent Prog Horm Res 59:409-424
103. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, Lank E, Bottomley B, Lopez-Fernandez J, Ferraz-Amaro I, Dattani MT, Ercan O, Myhre AG, Retterstol L, Stanhope R, Edge JA, McKenzie S, Lessan N, Ghodsi M, De Rosa V, Perna F, Fontana S, Barroso I, Undlien DE, O'Rahilly S (2007) Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 356:237-247 (Pubitemid 46143227)
104. Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, Lambert PD, Mataki C, Elliott PJ, Auwerx J (2008) Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 8:347-358
105. Feldmann HM, Golozoubova V, Cannon B, Nedergaard J (2009) UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt from thermal stress by living at thermoneutrality. Cell Metab 9:203-209
106. Festuccia WT, Oztezcan S, Laplante M, Berthiaume M, Michel C, Dohgu S, Denis RG, Brito MN, Brito NA, Miller DS, Banks WA, Bartness TJ, Richard D, Deshaies Y (2008) Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 149:2121-2130 (Pubitemid 351574485)
107. Finer N (2002) Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 26 (Suppl 4):S29-S33
108. Finkel T, Deng CX, Mostoslavsky R (2009) Recent progress in the biology and physiology of sirtuins. Nature 460:587-591
109. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E (2010) Obesity is an FGF21 resistant state. Diabetes 59(11):2781-2789
110. Flowers MT, Ntambi JM (2008) Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr Opin Lipidol 19:248-256 (Pubitemid 351653562)
111. Flowers MT, Ntambi JM (2009) Stearoyl-CoA desaturase and its relation to high-carbohydrate diets and obesity. Biochim Biophys Acta 1791:85-91
112. Flowers JB, Rabaglia ME, Schueler KL, Flowers MT, Lan H, Keller MP, Ntambi JM, Attie AD (2007) Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice. Diabetes 56:1228-1239 (Pubitemid 46715602)
113. Fogarty S, Hardie DG (2010) Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 1804:581-591
114. Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, Thorens B, Vaulont S, Viollet B (2005) Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 54:1331-1339 (Pubitemid 40586661)
115. Frederiksen L, Nielsen TL, Wraae K, Hagen C, Frystyk J, Flyvbjerg A, Brixen K, Andersen M (2009) Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. J Clin Endocrinol Metab 94:4010-4015
116. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010 (Pubitemid 32165613)
117. Fujii N, Ho RC, Manabe Y, Jessen N, Toyoda T, Holland WL, Summers SA, Hirshman MF, Goodyear LJ (2008) Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice. Diabetes 57:2958-2966
118. Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, Hanson R, Hill JO, Hubbard V, Stamm E, Pi-Sunyer FX (2007) Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes 56:1680-1685 (Pubitemid 46842603)
119. Galgani JE, Moro C, Ravussin E (2008) Metabolic flexibility and insulin resistance. Am J Physiol Endocrinol Metab 295:E1009-E1017
120. Gallwitz B (2011) GLP-1-agonists and dipeptidyl-peptidase IV inhibitors. Handb Exp Pharmacol. doi:10.1007/978-3-642-17214-4-3
121. Gauna C, Kiewiet RM, Janssen JA, van de Zande B, Delhanty PJ, Ghigo E, Hofland LJ, Themmen AP, van der Lely AJ (2007) Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab 293:E697-E704 (Pubitemid 47358981)
122. Gavrilova O, Marcus-Samuels B, Reitman ML (2000) Lack of responses to a b3-adrenergic agonist in lipoatrophic A-ZIP/F-1 mice. Diabetes 49:1910-1916
123. Gloaguen I, Costa P, Demartis A, Lazzaro D, Dimarco A, Graziani R, Paonessa G, Chen F, Rosenblum CI, Vanderploeg LT, Cortese R, Ciliberto G, Laufer R (1997) Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci USA 94:6456-6461 (Pubitemid 27270706)
124. Golay A (2008) Metformin and body weight. Int J Obes (Lond) 32:61-72
125. Golozoubova V, Gullberg H, Matthias A, Cannon B, Vennstrom B, Nedergaard J (2004) Depressed thermogenesis but competent brown adipose tissue recruitment in mice devoid of all hormone-binding thyroid hormone receptors. Mol Endocrinol 18:384-401 (Pubitemid 38183937)
126. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F (2002) A peripheral mechanism for CB1 cannabinoid receptordependent modulation of feeding. J Neurosci 22:9612-9617 (Pubitemid 35356203)
127. Gonez LJ, Naselli G, Banakh I, Niwa H, Harrison LC (2008) Pancreatic expression and mitochondrial localization of the progestin-adipoQ receptor PAQR10. Mol Med 14:697-704
128. Granneman JG, Li P, Zhu Z, Lu Y (2005) Metabolic and cellular plasticity in white adipose tissue I: effects of beta3-adrenergic receptor activation. Am J Physiol Endocrinol Metab 289: E608-E616 (Pubitemid 41356082)
129. Grover GJ, Mellstrom K, Malm J (2007) Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes. Curr Vasc Pharmacol 5:141-154
130. Grujic D, Susulic VS, Harper ME, Himms-Hagen J, Cunningham BA, Corkey BE, Lowell BB (1997) b3-adrenergic receptors on white and brown adipocytes mediate b3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. J Biol Chem 272:17686-17693 (Pubitemid 27311206)
131. Gualillo O, Lago F, Dieguez C (2008) Introducing GOAT: a target for obesity and anti-diabetic drugs? Trends Pharmacol Sci 29:398-401
132. Gutierrez-Juarez R, Pocai A, Mulas C, Ono H, Bhanot S, Monia BP, Rossetti L (2006) Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest 116:1686-1695
133. Hagberg JM, Park JJ, Brown MD (2000) The role of exercise training in the
134. Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, Madden JF (2001) Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 7:846-853 (Pubitemid 32708720)
135. Hall KD, Hallgreen CE (2008) Increasing weight loss attenuates the preferential loss of visceral compared with subcutaneous fat: a predicted result of an allometric model. Int J Obes (Lond) 32:722 (Pubitemid 351536024)
136. Hallgreen CE, Hall KD (2008) Allometric relationship between changes of visceral fat and total fat mass. Int J Obes (Lond) 32:845-852 (Pubitemid 351670611)
137. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A (1998) Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68:1180-1186 (Pubitemid 28550946)
138. Harada N, Oda Z, Hara Y, Fujinami K, Okawa M, Ohbuchi K, Yonemoto M, Ikeda Y, Ohwaki K, Aragane K, Tamai Y, Kusunoki J (2007) Hepatic de novo lipogenesis is present in liverspecific ACC1-deficient mice. Mol Cell Biol 27:1881-1888
139. Harder H, Nielsen L, Tu DT, Astrup A (2004) The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 27:1915-1921 (Pubitemid 38989232)
140. Hardie DG (2008) AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 32(suppl 4): S7-S12
141. Harrington WW, Britt CS, Wilson JG, Milliken NO, Binz JG, Lobe DC, Oliver WR, Lewis MC, Ignar DM (2007) The effect of PPARα, PPARδ, PPARγ, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice. PPAR Res 2007:97125
142. Harwood HJ Jr, Petras SF, Shelly LD, Zaccaro LM, Perry DA, Makowski MR, Hargrove DM, Martin KA, Tracey WR, Chapman JG, Magee WP, Dalvie DK, Soliman VF, Martin WH, Mularski CJ, Eisenbeis SA (2003) Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 278:37099-37111
143. Havel RJ, Carlson LA, Ekelund LG, Holmgren A (1964) Studies on the relation between mobilization of free fatty acids and energy metabolism in man: effects of norepinephrine and nicotinic acid. Metabolism 13:1402-1412
144. Hawley JA, Holloszy JO (2009) Exercise: it's the real thing! Nutr Rev 67:172-178
145. Hawley JA, Lessard SJ (2008) Exercise training-induced improvements in insulin action. Acta Physiol (Oxf) 192:127-135 (Pubitemid 350265363)
146. Hayes C, Kriska A (2008) Role of physical activity in diabetes management and prevention. J Am Diet Assoc 108:S19-S23 (Pubitemid 351389295)
147. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI (1997) Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 100:270-278 (Pubitemid 27349073)
148. Hegarty BD, Furler SM, Ye J, Cooney GJ, Kraegen EW (2003) The role of intramuscular lipid in insulin resistance. Acta Physiol Scand 178:373-383 (Pubitemid 36960428)
149. Hegarty BD, Turner N, Cooney GJ, Kraegen EW (2009) Insulin resistance and fuel homeostasis: the role of AMP-activated protein kinase. Acta Physiol (Oxf) 196:129-145
150. Herling AW, Gossel M, Haschke G, Stengelin S, Kuhlmann J, Muller G, Schmoll D, Kramer W (2007) CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 293:E826-E832 (Pubitemid 47358996)
151. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W (2008) Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 149:2557-2566 (Pubitemid 351574492)
152. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R (2005) 11b-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517-527
153. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M (1999) Recombinant leptin for weight loss in obese and lean adults, A randomized, controlled, dose-escalation trial. JAMA 282:1568-1575 (Pubitemid 29504050)
154. Himms-Hagen J (1997) On raising energy expenditure in ob/ob mice. Science 276:1132-1133
155. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ (1998) Biological evaluation of a lipidmobilizing factor isolated from the urine of cancer patients. Cancer Res 58:2359-2365 (Pubitemid 28252695)
156. Hocking SL, Chisholm DJ, James DE (2008) Studies of regional adipose transplantation reveal a unique and beneficial interaction between subcutaneous adipose tissue and the intra-abdominal compartment. Diabetologia 51:900-902
157. Hofer D, Raices M, Schauenstein K, Porta S, Korsatko W, Hagmuller K, Zaninovich A (2000) The in vivo effects of beta-3-receptor agonist CGP-12177 on thyroxine deiodination in coldexposed, sympathectomized rat brown fat. Eur J Endocrinol 143:273-277 (Pubitemid 30622363)
158. Hollander P (2007) Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am J Med 120:S18-S28; discussion S29-S32
159. Holloszy JO (2005) Exercise-induced increase in muscle insulin sensitivity. J Appl Physiol 99:338-343
160. Holst B, Schwartz TW (2006) Ghrelin receptor mutations-too little height and too much hunger. J Clin Invest 116:637-641 (Pubitemid 43326872)
161. Hood DA, Irrcher I, Ljubicic V, Joseph AM (2006) Coordination of metabolic plasticity in skeletal muscle. J Exp Biol 209:2265-2275 (Pubitemid 44065521)
162. Hoogwerf BJ, Doshi KB, Diab D (2008) Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag 4:355-362 (Pubitemid 351711964)
163. Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, He CT, Lee CH, Fan SC, Sheu WH (2005) Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. Diabet Med 22:1024-1030 (Pubitemid 41025999)
164. Inhoff T, Wiedenmann B, Klapp BF, Monnikes H, Kobelt P (2009) Is desacyl ghrelin a modulator of food intake? Peptides 30:991-994
165. Islam-Ali B, Khan S, Price SA, Tisdale MJ (2001) Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br J Cancer 85:758-763 (Pubitemid 32929477)
166. Issandou M, Bouillot A, Brusq JM, Forest MC, Grillot D, Guillard R, Martin S, Michiels C, Sulpice T, Daugan A (2009) Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models. Eur J Pharmacol 618:28-36
167. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni IP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363:905-917
168. Janiszewski PM, Kuk JL, Ross R (2008) Is the reduction of lower-body subcutaneous adipose tissue associated with elevations in risk factors for diabetes and cardiovascular disease? Diabetologia 51:1475-1482
169. Janssen I, Fortier A, Hudson R, Ross R (2002) Effects of an energy-restrictive diet with or without exercise on abdominal fat, intermuscular fat, and metabolic risk factors in obese women. Diabetes Care 25:431-438 (Pubitemid 41103332)
170. Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M, Ronan J, Esau C, Murphy C, Szalkowski D, Bergeron R, Doebber T, Zhang BB (2005) Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 115:1030-1038 (Pubitemid 40489408)
171. Johansson L, Fotsch C, Bartberger MD, Castro VM, Chen M, Emery M, Gustafsson S, Hale C, Hickman D, Homan E, Jordan SR, Komorowski R, Li A, McRae K, Moniz G, Matsumoto G, Orihuela C, Palm G, Veniant M, Wang M, Williams M, Zhang J (2008) 2-amino-1, 3-thiazol-4 (5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice. J Med Chem 51:2933-2943 (Pubitemid 351706022)
172. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439-451 (Pubitemid 40686653)
173. Karlsson HK, Hallsten K, Bjornholm M, Tsuchida H, Chibalin AV, Virtanen KA, Heinonen OJ, Lonnqvist F, Nuutila P, Zierath JR (2005) Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes 54:1459-1467 (Pubitemid 40586678)
174. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M (2003) A G protein-coupled receptor responsive to bile acids. J Biol Chem 278:9435-9440 (Pubitemid 36800434)
175. Keates AC, Bailey CJ (1993) Metformin does not increase energy expenditure of brown fat. Biochem Pharmacol 45:971-973 (Pubitemid 23071449)
176. Kennedy BL, Ellis S (1969) Dissociation of catecholamine-induced calorigenesis from lipolysis and glycogenolysis in intact animals. J Pharmacol Exp Ther 168:137-145
177. Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Pan Q, Garvey WT (1997) The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 82:1293-1300 (Pubitemid 27166679)
178. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS (2005) Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54:1023-1031 (Pubitemid 40446315)
179. King AJ, Segreti JA, Larson KJ, Souers AJ, Kym PR, Reilly RM, Collins CA, Voorbach MJ, Zhao G, Mittelstadt SW, Cox BF (2010) In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia. Eur J Pharmacol 637:155-161
180. Kirchner H, Gutierrez JA, Solenberg PJ, Pfluger PT, Czyzyk TA, Willency JA, Schurmann A, Joost HG, Jandacek RJ, Hale JE, Heiman ML, Tschop MH (2009) GOAT links dietary lipids with the endocrine control of energy balance. Nat Med 15:741-745
181. Kola B (2008) Role of AMP-activated protein kinase in the control of appetite. J Neuroendocrinol 20:942-951
182. Koltun DO, Vasilevich NI, Parkhill EQ, Glushkov AI, Zilbershtein TM, Mayboroda EI, Boze MA, Cole AG, Henderson I, Zautke NA, Brunn SA, Chu N, Hao J, Mollova N, Leung K, Chisholm JW, Zablocki J (2009) Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett 19:3050-3053
183. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, Fischer CP, Lindegaard B, Petersen AM, Taudorf S, Secher NH, Pilegaard H, Bruunsgaard H, Pedersen BK (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50:431-438
184. Kraegen EW, Cooney GJ (2008) Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 19:235-241 (Pubitemid 351653560)
185. Kramer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A (2007) Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 282:19313-19320 (Pubitemid 47100082)
186. Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, Mineyama T, Ishikawa M, Moroi M, Sugi K, Yamauchi T, Ueki K, Tobe K, Noda T, Nagai R, Kadowaki T (2006) Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 281:8748-8755 (Pubitemid 43847980)
187. Kunos G, Osei-Hyiaman D, Batkai S, Sharkey KA, Makriyannis A (2009) Should peripheral CB (1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 30:1-7
188. Kunz I, Meier MK, Bourson A, Fisseha M, Schilling W (2008) Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. Int J Obes (Lond) 32:863-870 (Pubitemid 351670628)
189. Kusakabe T, Tanioka H, Ebihara K, Hirata M, Miyamoto L, Miyanaga F, Hige H, Aotani D, Fujisawa T, Masuzaki H, Hosoda K, Nakao K (2009) Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet. Diabetologia 52:675-683
190. Lafontan M, Piazza PV, Girard J (2007) Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab 33:85-95 (Pubitemid 46562582)
191. Lafrance L, Routhier D, Tetu B, Tetu C (1979) Effects of noradrenaline and nicotinic acid on plasma free fatty acids and oxygen consumption in cold-adapted rats. Can J Physiol Pharmacol 57:725-730 (Pubitemid 9247356)
192. Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ (2001) Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA 98:4652-4657 (Pubitemid 32295031)
193. Lane MD, Wolfgang M, Cha SH, Dai Y (2008) Regulation of food intake and energy expenditure by hypothalamic malonyl-CoA. Int J Obes (Lond) 32(suppl 4):S49-S54
194. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, Tomas E (2006) Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 291:E175-E181 (Pubitemid 44035323)
195. Lee SH, Dobrzyn A, Dobrzyn P, Rahman SM, Miyazaki M, Ntambi JM (2004) Lack of stearoyl-CoA desaturase 1 upregulates basal thermogenesis but causes hypothermia in a cold environment. J Lipid Res 45:1674-1682 (Pubitemid 39296207)
196. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM (2006) PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103:3444-3449 (Pubitemid 43346488)
197. Liang F, Kume S, Koya D (2009) SIRT1 and insulin resistance. Nat Rev Endocrinol 5:367-373
198. Liu X, Perusse F, Bukowiecki LJ (1998) Mechanisms of the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker-ZDF rats. Am J Physiol 274:R1212-R1219
199. Liu L, Zhang Y, Chen N, Shi X, Tsang B, Yu YH (2007) Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. J Clin Invest 117:1679-1689 (Pubitemid 46871352)
200. Livingston EH (2006) Lower body subcutaneous fat accumulation and diabetes mellitus risk. Surg Obes Relat Dis 2:362-368
201. Livingstone DE, Walker BR (2003) Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther 305:167-172 (Pubitemid 36373847)
202. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP (2000) Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288:2379-2381 (Pubitemid 30448165)
203. Longo KA, Charoenthongtrakul S, Giuliana DJ, Govek EK, McDonagh T, Qi Y, DiStefano PS, Geddes BJ (2008) Improved insulin sensitivity and metabolic flexibility in ghrelin receptor knockout mice. Regul Pept 150:55-61
204. Madsen AN, Jelsing J, van de Wall EH, Vrang N, Larsen PJ, Schwartz GJ (2009) Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents. Neurosci Lett 449:20-23
205. Man WC, Miyazaki M, Chu K, Ntambi J (2006) Colocalization of SCD1 and DGAT2: implying preference for endogenous monounsaturated fatty acids in triglyceride synthesis. J Lipid Res 47:1928-1939 (Pubitemid 44401980)
206. Manara L, Badone D, Baroni M, Boccardi G, Cecchi R, Croci T, Giudice A, Guzzi U, Landi M, Le Fur G (1996) Functional identification of rat atypical β-adrenoceptors by the first b3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol 117:435-442 (Pubitemid 26057651)
207. Maneuf Y, Higginbottom M, Pritchard M, Lione L, Ashford MLJ, Richardson PJ (2004) Small molecule leptin mimetics overcome leptin resistance in obese rats. Fundam Clin Pharmacol 18 (suppl 1):83
208. Mano-Otagiri A, Iwasaki-Sekino A, Nemoto T, Ohata H, Shuto Y, Nakabayashi H, Sugihara H, Oikawa S, Shibasaki T (2010) Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats. Regul Pept 160:81-90
209. Mao J, DeMayo FJ, Li H, Abu-Elheiga L, Gu Z, Shaikenov TE, Kordari P, Chirala SS, Heird WC, Wakil SJ (2006) Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci USA 103:8552-8557 (Pubitemid 43838493)
210. Marrades MP, Martinez JA, Moreno-Aliaga MJ (2008) ZAG, a lipid mobilizing adipokine, is downregulated in human obesity. J Physiol Biochem 64:61-66 (Pubitemid 351997494)
211. Marsicano G, Lutz B (2006) Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest 29:27-46
212. Masaki T, Chiba S, Yasuda T, Tsubone T, Kakuma T, Shimomura I, Funahashi T, Matsuzawa Y, Yoshimatsu H (2003) Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice. Diabetes 52:2266-2273 (Pubitemid 37059496)
213. Matthews VB, Febbraio MA (2008) CNTF: a target therapeutic for obesity-related metabolic disease? J Mol Med 86:353-361
214. Matthews VB, Astrom MB, Chan MH, Bruce CR, Krabbe KS, Prelovsek O, Akerstrom T, Yfanti C, Broholm C, Mortensen OH, Penkowa M, Hojman P, Zankari A, Watt MJ, Bruunsgaard H, Pedersen BK, Febbraio MA (2009) Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia 52:1409-1418
215. Mayorov AV, Amara N, Chang JY, Moss JA, Hixon MS, Ruiz DI, Meijler MM, Zorrilla EP, Janda KD (2008) Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice. Proc Natl Acad Sci USA 105:17487-17492
216. Meex RC, Schrauwen-Hinderling VB, Moonen-Kornips E, Schaart G, Mensink M, Phielix E, van de Weijer T, Sels JP, Schrauwen P, Hesselink MK (2010) Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity. Diabetes 59:572-579
217. Menshikova EV, Ritov VB, Ferrell RE, Azuma K, Goodpaster BH, Kelley DE (2007) Characteristics of skeletal muscle mitochondrial biogenesis induced by moderate-intensity exercise and weight loss in obesity. J Appl Physiol 103:21-27 (Pubitemid 47092273)
218. Mesaros A, Koralov SB, Rother E, Wunderlich FT, Ernst MB, Barsh GS, Rajewsky K, Bruning JC (2008) Activation of Stat3 signaling in AgRP neurons promotes locomotor activity. Cell Metab 7:236-248 (Pubitemid 351297558)
219. Migrenne S, Lacombe A, Lefevre AL, Pruniaux MP, Guillot E, Galzin AM, Magnan C (2009) Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 296:R929-R935
220. Mikhail N (2008) Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Invest Drugs 17:845-853
221. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712-716 (Pubitemid 350207685)
222. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415:339-343 (Pubitemid 34087557)
223. Mirshamsi S, Olsson M, Arnelo U, Kinsella JM, Permert J, Ashford ML (2007) BVT.3531 reduces body weight and activates K(ATP) channels in isolated arcuate neurons in rats. Regul Pept 141:19-24 (Pubitemid 46482687)
224. Mitchell TH, Ellis RD, Smith SA, Robb G, Cawthorne MA (1989) Effects of BRL 35135, a β-adrenoceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects. Int J Obes 13:757-766 (Pubitemid 20151759)
225. Miyazaki M, Sampath H, Liu X, Flowers MT, Chu K, Dobrzyn A, Ntambi JM (2009) Stearoyl- CoA desaturase-1 deficiency attenuates obesity and insulin resistance in leptin-resistant obese mice. Biochem Biophys Res Commun 380:818-822
226. Mjos OD (1971) Effect of inhibition of lipolysis on myocardial oxygen consumption in the presence of isoproterenol. J Clin Invest 50:1869-1873
227. Mnich SJ, Hiebsch RR, Huff RM, Muthian S (2010) Anti-inflammatory properties of CB1-receptor antagonist involves beta2 adrenoceptors. J Pharmacol Exp Ther 333:445-453
228. Montecucco F, Steffens S, Mach F (2008) Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm 2008:767623
229. Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55 (Suppl 2):S9-S15 (Pubitemid 44927027)
230. Morrison SF (2001) Differential regulation of sympathetic outflows to vasoconstrictor and thermoregulatory effectors. Ann NY Acad Sci 940:286-298
231. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR (2004) Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931-938 (Pubitemid 38436604)
232. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662-5667 (Pubitemid 36034375)
233. Mullen KL, Pritchard J, Ritchie I, Snook LA, Chabowski A, Bonen A, Wright D, Dyck DJ (2009) Adiponectin resistance precedes the accumulation of skeletal muscle lipids and insulin resistance in high-fat-fed rats. Am J Physiol Regul Integr Comp Physiol 296:R243-R251
234. Murase T, Misawa K, Haramizu S, Minegishi Y, Hase T (2010) Nootkatone, a characteristic constituent of grapefruit, stimulates energy metabolism and prevents diet-induced obesity by activating AMPK. Am J Physiol Endocrinol Metab 299:E266-E275
235. Nakagawa T, Ogawa Y, Ebihara K, Yamanaka M, Tsuchida A, Taiji M, Noguchi H, Nakao K (2003) Anti-obesity and anti-diabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance. Int J Obes Relat Metab Disord 27:557-565 (Pubitemid 36561012)
236. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194-198 (Pubitemid 32144284)
237. Narasimhan ML, Coca MA, Jin J, Yamauchi T, Ito Y, Kadowaki T, Kim KK, Pardo JM, Damsz B, Hasegawa PM, Yun DJ, Bressan RA (2005) Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 17:171-180 (Pubitemid 40138613)
238. Niederhoffer N, Schmid K, Szabo B (2003) The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol 367:434-443 (Pubitemid 36718294)
239. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschop J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschop MH (2008) Peripheral, but not central, CB1 antagonism provides food intake independent metabolic benefits in diet-induced obese rats. Diabetes 57(11):2977-2991
240. Nonomura T, Tsuchida A, Ono-Kishino M, Nakagawa T, Taiji M, Noguchi H (2001) Brain-derived neurotrophic factor regulates energy expenditure through the central nervous system in obese diabetic mice. Int J Exp Diabetes Res 2:201-209
241. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM, Attie AD (2002) Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 99:11482-11486 (Pubitemid 34920951)
242. O'Gorman DJ, Krook A (2008) Exercise and the treatment of diabetes and obesity. Endocrinol Metab Clin North Am 37:887-903
243. Ohkawara K, Tanaka S, Miyachi M, Ishikawa-Takata K, Tabata I (2007) A dose-response relation between aerobic exercise and visceral fat reduction: systematic review of clinical trials. Int J Obes (Lond) 31:1786-1797 (Pubitemid 350174632)
244. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311 (Pubitemid 32397124)
245. Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roque IFM, Richter B, Mauricio D (2008) Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev:CD003054
246. Osaka T, Tsukamoto A, Koyama Y, Inoue S (2008) Central and peripheral administration of amylin induces energy expenditure in anesthetized rats. Peptides 29:1028-1035
247. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305 (Pubitemid 40629049)
248. Ott V, Fasshauer M, Dalski A, Klein HH, Klein J (2002) Direct effects of ciliary neurotrophic factor on brown adipocytes: evidence for a role in peripheral regulation of energy homeostasis. J Endocrinol 173:R1-R8 (Pubitemid 34552467)
249. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348 (Pt 3):607-614 (Pubitemid 30410251)
250. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers MG Jr, Ozcan U (2009) Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 9:35-51
251. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285:8340-8351
252. Packard GC, Boardman TJ (1999) The use of percentages and size-specific indices to normalise physiological data for variation in body size: wasted time wasted effort? Comp Biochem Physiol A 122:37-44
253. Paolisso G, Amato L, Eccellente R, Gambardella A, Tagliamonte MR, Varricchio G, Carella C, Giugliano D, D'Onofrio F (1998) Effect of metformin on food intake in obese subjects. Eur J Clin Invest 28:441-446 (Pubitemid 28326408)
254. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MH (2003) Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 88:1637-1645 (Pubitemid 36623381)
255. Pavon FJ, Serrano A, Perez-Valero V, Jagerovic N, Hernandez-Folgado L, Bermudez-Silva FJ, Macias M, Goya P, de Fonseca FR (2008) Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 20(Suppl 1):116-123 (Pubitemid 351552685)
256. Pencek RR, Shearer J, Camacho RC, James FD, Lacy DB, Fueger PT, Donahue EP, Snead W, Wasserman DH (2005) 5-Aminoimidazole-4-carboxamide-1-beta-D- ribofuranoside causes acute hepatic insulin resistance in vivo. Diabetes 54:355-360
257. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB (1994) Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43:920-928
258. Perrin D, Mamet J, Geloen A, Morel G, Dalmaz Y, Pequignot JM (2003) Sympathetic and brain monoaminergic regulation of energy balance in obesity-resistant rats (Lou/C). Auton Neurosci 109:1-9 (Pubitemid 37443663)
259. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor beta(delta). Mol Cell Biol 20:5119-5128 (Pubitemid 30431565)
260. Pfluger PT, Kirchner H, Gunnel S, Schrott B, Perez-Tilve D, Fu S, Benoit SC, Horvath T, Joost HG, Wortley KE, Sleeman MW, Tschop MH (2008) Simultaneous deletion of ghrelin and its receptor increases motor activity and energy expenditure. Am J Physiol Gastrointest Liver Physiol 294:G610-G618 (Pubitemid 351468766)
261. Pinnamaneni SK, Southgate RJ, Febbraio MA, Watt MJ (2006) Stearoyl CoA desaturase 1 is elevated in obesity but protects against fatty acid-induced skeletal muscle insulin resistance in vitro. Diabetologia 49:3027-3037 (Pubitemid 44730307)
262. Pirola L, Frojdo S (2008) Resveratrol: one molecule, many targets. IUBMB Life 60:323-332
263. Popeijus HE, Saris WH, Mensink RP (2008) Role of stearoyl-CoA desaturases in obesity and the metabolic syndrome. Int J Obes (Lond) 32:1076-1082 (Pubitemid 351986202)
264. Porter SA, Massaro JM, Hoffmann U, Vasan RS, O'Donnel CJ, Fox CS (2009) Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care 32:1068-1075
265. Pratley RE (2008) Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med 10:171
266. Proietto J, Thorburn AW (2003) The therapeutic potential of leptin. Expert Opin Invest Drugs 12:373-378 (Pubitemid 36336409)
267. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS (2004) Adiponectin acts in the brain to decrease body weight. Nat Med 10:524-529 (Pubitemid 38667912)
268. Qi L, Hu FB, Hu G (2008) Genes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changes. Curr Mol Med 8:519-532
269. Rahmouni K, Morgan DA (2007) Hypothalamic arcuate nucleus mediates the sympathetic and arterial pressure responses to leptin. Hypertension 49:647-652
270. Ribeiro MO (2008) Effects of thyroid hormone analogs on lipid metabolism and thermogenesis. Thyroid 18:197-203
271. Riboulet-Chavey A, Diraison F, Siew LK, Wong FS, Rutter GA (2008) Inhibition of AMPactivated protein kinase protects pancreatic beta-cells from
272. Rodgers JT, Puigserver P (2007) Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA 104:12861-12866 (Pubitemid 47255245)
273. Rodriguez A, Gomez-Ambrosi J, Catalan V, Gil MJ, Becerril S, Sainz N, Silva C, Salvador J, Colina I, Fruhbeck G (2009) Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 33:541-552
274. Rohrbach KW, Han S, Gan J, O'Tanyi EJ, Zhang H, Chi CL, Taub R, Largent BL, Cheng D (2005) Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents. Eur J Pharmacol 511:31-41 (Pubitemid 40380642)
275. Rolli V, Radosavljevic M, Astier V, Macquin C, Castan-Laurell I, Visentin V, Guigne C, Carpene C, Valet P, Gilfillan S, Bahram S (2007) Lipolysis is altered in MHC class I zinc-alpha(2)- glycoprotein deficient mice. FEBS Lett 581:394-400 (Pubitemid 46157227)
276. Ronnebaum SM, Joseph JW, Ilkayeva O, Burgess SC, Lu D, Becker TC, Sherry AD, Newgard CB (2008) Chronic suppression of acetyl-CoA carboxylase 1 in beta-cells impairs insulin secretion via inhibition of glucose rather than lipid metabolism. J Biol Chem 283:14248-14256
277. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R (2010) The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33:1516-1522
278. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD (2008) Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 105:7257-7262 (Pubitemid 351754465)
279. Rubio A, Raasmaja A, Maia AL, Kim KR, Silva JE (1995) Effects of thyroid hormone on norepinephrine signaling in brown adipose tissue. I. Beta 1- and beta 2-adrenergic receptors and cyclic adenosine 30, 50-monophosphate generation. Endocrinology 136:3267-3276
280. Rudolph J, Esler WP, O'Connor S, Coish PD, Wickens PL, Brands M, Bierer DE, Bloomquist BT, Bondar G, Chen L, Chuang CY, Claus TH, Fathi Z, Fu W, Khire UR, Kristie JA, Liu XG, Lowe DB, McClure AC, Michels M, Ortiz AA, Ramsden PD, Schoenleber RW, Shelekhin TE, Vakalopoulos A, Tang W, Wang L, Yi L, Gardell SJ, Livingston JN, Sweet LJ, Bullock WH (2007) Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J Med Chem 50:5202-5216 (Pubitemid 47585718)
281. Ruilope LM, Despres JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, Van Gaal L (2008) Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens 26:357-367
282. Russell ST, Tisdale MJ (2002) Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo. Br J Cancer 87:580-584
283. Russell ST, Tisdale MJ (2010) Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice. Endocrinology 151:948-957
284. Russell ST, Hirai K, Tisdale MJ (2002) Role of b3-adrenergic receptors in the action of a tumour lipid mobilizing factor. Br J Cancer 86:424-428 (Pubitemid 34185128)
285. Rutanen J, Yaluri N, Modi S, Pihlajamaki J, Vanttinen M, Itkonen P, Kainulainen S, Yamamoto H, Lagouge M, Sinclair DA, Elliott P, Westphal C, Auwerx J, Laakso M (2010) SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity. Diabetes 59:829-835
286. Rutter GA, Parton LE (2008) The beta-cell in type 2 diabetes and in obesity. Front Horm Res 36:118-134
287. Ryu GR, Lee MK, Lee E, Ko SH, Ahn YB, Kim JW, Yoon KH, Song KH (2009) Activation of AMP-activated protein kinase mediates acute and severe hypoxic injury to pancreatic beta cells. Biochem Biophys Res Commun 386:356-362
288. Saeedi R, Parsons HL, Wambolt RB, Paulson K, Sharma V, Dyck JR, Brownsey RW, Allard MF (2008) Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am J Physiol Heart Circ Physiol 294:H2497-H2506
289. Salome N, Hansson C, Taube M, Gustafsson-Ericson L, Egecioglu E, Karlsson-Lindahl L, Fehrentz JA, Martinez J, Perrissoud D, Dickson SL (2009) On the central mechanism underlying ghrelin's chronic pro-obesity effects in rats: new insights from studies exploiting a potent ghrelin receptor (GHS-R1A) antagonist. J Neuroendocrinol 21(9):777-85
290. Sampath H, Flowers MT, Liu X, Paton CM, Sullivan R, Chu K, Zhao M, Ntambi JM (2009) Skinspecific deletion of stearoyl-CoA desaturase-1 alters skin lipid composition and protects mice from high-fat diet-induced obesity. J Biol Chem 284(30):19961-73
291. Sanders PM, Tisdale MJ (2004a) Effect of zinc-alpha2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett 212:71-81 (Pubitemid 38887722)
292. Sanders PM, Tisdale MJ (2004b) Role of lipid-mobilising factor (LMF) in protecting tumour cells from oxidative damage. Br J Cancer 90:1274-1278 (Pubitemid 38496824)
293. Sarruf DA, Thaler JP, Morton GJ, German J, Fischer JD, Ogimoto K, Schwartz MW (2010) Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59:1817-1824
294. Scheen AJ (2008) CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol 20(Suppl 1):139-146
295. Schiff M, Loublier S, Coulibaly A, Benit P, de Baulny HO, Rustin P (2009) Mitochondria and diabetes mellitus: untangling a conflictive relationship? J Inherit Metab Dis 32:684-698
296. Schiffelers SL, Brouwer EM, Saris WH, van Baak MA (1998) Inhibition of lipolysis reduces β1-adrenoceptor-mediated thermogenesis in man. Metabolism 47:1462-1467 (Pubitemid 28565528)
297. Schiffelers SL, Blaak EE, Saris WH, van Baak MA (2000) In vivo b3-adrenergic stimulation of human thermogenesis and lipid use. Clin Pharmacol Ther 67:558-566
298. Schmidt MI, Duncan BB, Vigo A, Pankow JS, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G (2006) Leptin and incident type 2 diabetes: risk or protection? Diabetologia 49:2086-2096
299. Schmitz-Peiffer C, Craig DL, Biden TJ (1999) Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 274:24202-24210
300. Schrauwen P, Hesselink MK (2008) Reduced tricarboxylic acid cycle flux in type 2 diabetes mellitus? Diabetologia 51:1694-1697
301. Schreurs M, van Dijk TH, Gerding A, Havinga R, Reijngoud DJ, Kuipers F (2009) Soraphen, an inhibitor of the acetyl-CoA carboxylase system, improves peripheral insulin sensitivity in mice fed a high-fat diet. Diabetes Obes Metab 11(10):987-91
302. 1/2-) and atypical β-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel b3-adrenoceptor agonists of differing selectivities. J Pharmacol Exp Ther 285:1084-1095
303. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646 (Pubitemid 41780780)
304. Shetty S, Kusminski CM, Scherer PE (2009) Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 30:234-239
305. Sleeman MW, Garcia K, Liu R, Murray JD, Malinova L, Moncrieffe M, Yancopoulos GD, Wiegand SJ (2003) Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice. Proc Natl Acad Sci USA 100:14297-14302 (Pubitemid 37499231)
306. Slentz CA, Houmard JA, Kraus WE (2009) Exercise, abdominal obesity, skeletal muscle, and metabolic risk: evidence for a dose response. Obesity (Silver Spring) 17(suppl 3):S27-S33
307. Smith SA, Sennitt MV, Cawthorne MA (1990) BRL 35135: an orally active antihyperglycaemic agent with weight reducing effects. In: Bailey CJ, Flatt PR (eds) New antidiabetic drugs. Smith-Gordon, London, pp 177-189
308. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, Eckel RH, Farese RV Jr (2000) Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat Genet 25:87-90 (Pubitemid 30257043)
309. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C (2008) Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 31:1816-1823
310. Soares JB, Leite-Moreira AF (2008) Ghrelin, des-acyl ghrelin and obestatin: three pieces of the same puzzle. Peptides 29:1255-1270
311. Son MH, Kim HD, Chae YN, Kim MK, Shin CY, Ahn GJ, Choi SH, Yang EK, Park KJ, Chae HW, Moon HS, Kim SH, Shin YG, Yoon SH (2010) Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J Obes (Lond) 34:547-556
312. Soulage C, Zarrouki B, Soares AF, Lagarde M, Geloen A (2008) Lou/C obesity-resistant rat exhibits hyperactivity, hypermetabolism, alterations in white adipose tissue cellularity, and lipid tissue profiles. Endocrinology 149:615-625 (Pubitemid 351159326)
313. Speakman JR (2010) FTO effect on energy demand versus food intake. Nature 464:E1; discussion E2
314. Strassburg S, Anker SD, Castaneda TR, Burget L, Perez-Tilve D, Pfluger PT, Nogueiras R, Halem H, Dong JZ, Culler MD, Datta R, Tschop MH (2008) Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats. Am J Physiol Endocrinol Metab 295:E78-E84
315. Sugimoto T, Ogawa W, Kasuga M, Yokoyama Y (2005) Chronic effects of AJ-9677 on energy expenditure and energy source utilization in rats. Eur J Pharmacol 519:135-145 (Pubitemid 43181176)
316. Sun Y, Ahmed S, Smith RG (2003) Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 23:7973-7981 (Pubitemid 37377491)
317. Sun Y, Asnicar M, Saha PK, Chan L, Smith RG (2006) Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab 3:379-386
318. Sun Y, Asnicar M, Smith RG (2007) Central and peripheral roles of ghrelin on glucose homeostasis. Neuroendocrinology 86:215-228 (Pubitemid 350073609)
319. Sundbom M, Kaiser C, Bjorkstrand E, Castro VM, Larsson C, Selen G, Nyhem CS, James SR (2008) Inhibition of 11betaHSD1 with the S- phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol 8:3
320. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr, Sternbach DD (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta) - synthesis and biological activity. Bioorg Med Chem Lett 13:1517-1521 (Pubitemid 36428550)
321. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J, Makriyannis A, Kunos G (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk inmouse models of obesity. JClin Invest 120:2953-2966
322. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924-15929 (Pubitemid 38021091)
323. Taslim S, Tai ES (2009) The relevance of the metabolic syndrome. Ann Acad Med Singapore 38:29-35
324. Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, Vettor R, Pasquali R, Carruba MO, Marsicano G, Lutz B, Pagotto U, Nisoli E (2008) Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 57:2028-2036
325. Teran-Garcia M, Rankinen T, Koza RA, Rao DC, Bouchard C (2005) Endurance training-induced changes in insulin sensitivity and gene expression. Am J Physiol Endocrinol Metab 288:E1168-E1178 (Pubitemid 40726804)
326. Terao A, Oikawa M, SaitoM(1994) Tissue-specific increase in norepinephrine turnover by central interleukin-1, but not by interleukin-6, in rats. Am J Physiol 266:R400-R404
327. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, Pfluger P, Castaneda TR, Muzzin P, Schurmann A, Szanto I, Tschop MH, Rohner-Jeanrenaud F (2006) Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 116:1983-1993 (Pubitemid 44033322)
328. Thomas EL, Brynes AE, McCarthy J, Goldstone AP, Hajnal JV, Saeed N, Frost G, Bell JD (2000) Preferential loss of visceral fat following aerobic exercise, measured by magnetic resonance imaging. Lipids 35:769-776 (Pubitemid 30624542)
329. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167-177
330. Thong FS, Lally JS, Dyck DJ, Greer F, Bonen A, Graham TE (2007) Activation of the A1 adenosine receptor increases insulin-stimulated glucose transport in isolated rat soleus muscle. Appl Physiol Nutr Metab 32:701-710
331. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP (2002) C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci USA 99:9498-9502 (Pubitemid 34764642)
332. Toth MJ (2001) Comparing energy expenditure data among individuals differing in body size and composition: statistical and physiological considerations. Curr Opin Clin Nutr Metab Care 4:391-397
333. Toyoshima Y, Gavrilova O, Yakar S, Jou W, Pack S, Asghar Z, Wheeler MB, LeRoith D (2005) Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology 146:4024-4035 (Pubitemid 41175774)
334. Treebak JT, Birk JB, Hansen BF, Olsen GS, Wojtaszewski JF (2009) A-769662 activates AMPK beta1-containing complexes but induces glucose uptake through a PI3-kinase-dependent pathway in mouse skeletal muscle. Am J Physiol Cell Physiol 297:C1041-C1052
335. Tseng YH, Cypess AM, Kahn CR (2010) Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov 9:465-482
336. Tsuchida A, Nonomura T, Ono-Kishino M, Nakagawa T, Taiji M, Noguchi H (2001) Acute effects of brain-derived neurotrophic factor on energy expenditure in obese diabetic mice. Int J Obes Relat Metab Disord 25:1286-1293 (Pubitemid 32835444)
337. Tu Y, Thupari JN, Kim EK, Pinn ML, Moran TH, Ronnett GV, Kuhajda FP (2005) C75 alters central and peripheral gene expression to reduce food intake and increase energy expenditure. Endocrinology 146:486-493 (Pubitemid 40051775)
338. Ukropcova B, Sereda O, de Jonge L, Bogacka I, Nguyen T, Xie H, Bray GA, Smith SR (2007) Family history of diabetes links impaired substrate switching and reduced mitochondrial content in skeletal muscle. Diabetes 56:720-727 (Pubitemid 46348476)
339. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59:554-563
340. Uto Y, Kiyotsuka Y, Ueno Y, Miyazawa Y, Kurata H, Ogata T, Deguchi T, Yamada M, Watanabe N, KonishiM, Kurikawa N, Takagi T,Wakimoto S, Kono K, Ohsumi J (2010) Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 10-{6-[5-(pyridin-3-ylmethyl)-1, 3, 4-oxadiazol-2-yl] pyridazin-3-yl}-5-(trif luoromethyl)-3, 4-dihydrospiro[chromene-2, 40-piperidine]. Bioorg Med Chem Lett 20:746-754
341. Vacher CM, Crepin D, Aubourg A, Couvreur O, Bailleux V, Nicolas V, Ferezou J, Gripois D, Gertler A, TaouisM(2008) A putative physiological role of hypothalamic CNTF in the control of energy homeostasis. FEBS Lett 582:3832-3838
342. Vaillancourt VA, Larsen SD, Tanis SP, Burr JE, Connell MA, Cudahy MM, Evans BR, Fisher PV, May PD, Meglasson MD, Robinson DD, Stevens FC, Tucker JA, Vidmar TJ, Yu JH (2001) Synthesis and biological activity of aminoguanidine and diaminoguanidine analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid. J Med Chem 44:1231-1248
343. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ (2006) Alphaglucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev:CD005061
344. van den Hoek AM, van Heijningen C, Schroder-van der Elst JP, Ouwens DM, Havekes LM, Romijn JA, Kalsbeek A, Pijl H (2008) Intracerebroventricular administration of neuropeptide Y induces hepatic insulin resistance via sympathetic innervation. Diabetes 57:2304-2310
345. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360:1500-1508
346. Venditti P, Chiellini G, Di Stefano L, Napolitano G, Zucchi R, Columbano A, Scanlan TS, Di Meo S (2010) The TRbeta-selective agonist, GC-1, stimulates mitochondrial oxidative processes to a lesser extent than triiodothyronine. J Endocrinol 205:279-289
347. Verty AN, Allen AM, Oldfield BJ (2009) The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity (Silver Spring) 17:254-261
348. Villicev CM, Freitas FR, Aoki MS, Taffarel C, Scanlan TS, Moriscot AS, Ribeiro MO, Bianco AC, Gouveia CH (2007) Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol 193:21-29 (Pubitemid 46638528)
349. Violett B, Andreelli F (2011) AMP-activated protein kinase and metabolic control. Handb Exp Pharmacol. doi:10.1007/978-3-642-17214-4-13
350. Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, Andreelli F, Ventura-Clapier R, Bertrand L (2009a) AMPK: Lessons from transgenic and knockout animals. Front Biosci 14:19-44
351. Viollet B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, Foretz M, Andreelli F (2009b) Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci 14:3380-3400
352. Virtanen KA, Rouru J, Hanninen V, Savontaus E, Rouvari T, Teirmaa T, Koulu M, Huupponen R (1997) Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism. Eur J Pharmacol 332:215-218 (Pubitemid 27341927)
353. Wakil SJ, Abu-Elheiga LA (2009) Fatty acid metabolism: target for metabolic syndrome. J Lipid Res 50(Suppl):S138-S143
354. Wang M (2006) Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr Opin Investig Drugs 7:319-323
355. Wang M (2011) Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Handb Exp Pharmacol. doi:10.1007/978-3-642-17214-4-6
356. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM (2003) Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113:159-170 (Pubitemid 36514968)
357. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, EvansRM (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2:e294
358. Wang SJ, Cornick C, O'Dowd J, Cawthorne MA, Arch JR (2007) Improved glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent on diet. Lipids Health Dis 6:2
359. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489 (Pubitemid 43152840)
360. Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I, Iwabu M, Awazawa M, Katsuyama H, Hasegawa C, Tokuyama K, Moroi M, Sugi K, Yamauchi T, Noda T, Nagai R, Terauchi Y, Tobe K, Ueki K, Kadowaki T (2009) Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 284:1803-1812
361. Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D, Kemp BE, Febbraio MA, Steinberg GR (2006a) CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12:541-548
362. Watt MJ, Hevener A, Lancaster GI, Febbraio MA (2006b) Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of c-Jun N-terminal kinase in peripheral tissues. Endocrinology 147:2077-2085
363. Weiss EP, Racette SB, Villareal DT, Fontana L, Steger-May K, Schechtman KB, Klein S, Holloszy JO (2006) Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr 84:1033-1042 (Pubitemid 44730373)
364. Wernstedt I, Edgley A, Berndtsson A, Faldt J, Bergstrom G, Wallenius V, Jansson JO (2006) Reduced stress- and cold-induced increase in energy expenditure in interleukin-6-deficient mice. Am J Physiol Regul Integr Comp Physiol 291:R551-R557 (Pubitemid 44352336)
365. Wilson S, Arch JR, Thurlby PL (1984) Genetically obese C57BL/6 ob/ob mice respond normally to sympathomimetic compounds. Life Sci 35:1301-1309 (Pubitemid 14068969)
366. Wilson S, Thurlby PL, Arch JR (1986) Substrate supply for thermogenesis induced by the β-adrenoceptor agonist BRL 26830A. Can J Physiol Pharmacol 65:113-119 (Pubitemid 17047170)
367. Wing RR, Phelan S (2005) Long-term weight loss maintenance. Am J Clin Nutr 82:222S-225S
368. Wortley KE, del Rincon JP, Murray JD, Garcia K, Iida K, Thorner MO, Sleeman MW (2005) Absence of ghrelin protects against early-onset obesity. J Clin Invest 115:3573-3578 (Pubitemid 43121845)
369. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, Bloom SR (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540-2547 (Pubitemid 33642772)
370. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Veniant MM (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250-259
371. Yamauchi T, Kadowaki T (2008) Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 32(suppl 7):S13-S18
372. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295 (Pubitemid 35373562)
373. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769 (Pubitemid 36735700)
374. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339 (Pubitemid 46376688)
375. Yang X, Smith U (2007) Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia 50:1127-1139
376. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI (2002) Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277:50230-50236 (Pubitemid 36042170)
377. Yu YH, Ginsberg HN (2004) The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism. Ann Med 36:252-261
378. Yudkin JS (2007) Insulin resistance and the metabolic syndrome - or the pitfalls of epidemiology. Diabetologia 50:1576-1586
379. Zammit VA, Buckett LK, Turnbull AV, Wure H, Proven A (2008) Diacylglycerol acyltransferases: potential roles as pharmacological targets. Pharmacol Ther 118:295-302
380. Zanuso S, Jimenez A, Pugliese G, Corigliano G, Balducci S (2010) Exercise for the management of type 2 diabetes: a review of the evidence. Acta Diabetol 47:15-22
381. Zhang BB, Zhou G, Li C (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9:407-416
382. Zhao G, Souers AJ, Voorbach M, Falls HD, Droz B, Brodjian S, Lau YY, Iyengar RR, Gao J, Judd AS, Wagaw SH, Ravn MM, Engstrom KM, Lynch JK, Mulhern MM, Freeman J, Dayton BD, Wang X, Grihalde N, Fry D, Beno DW, Marsh KC, Su Z, Diaz GJ, Collins CA, Sham H, Reilly RM, Brune ME, Kym PR (2008) Validation of diacyl glycerolacyltransferase i as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 51(3):380-3 (Pubitemid 351252263)
383. Zhou G, Sebhat IK, Zhang BB (2009) AMPK activators - potential therapeutics for metabolic and other diseases. Acta Physiol (Oxf) 196:175-190
384. Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, Jones JE, Deysher AE, Waxman AR, White RD, Williams TD, Lachey JL, Seeley RJ, Lowell BB, Elmquist JK (2005) Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 115:3564-3572 (Pubitemid 43121844)
385. Zinker B, Mika A, Nguyen P, Wilcox D, Ohman L, von Geldern TW, Opgenorth T, Jacobson P (2007) Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance. Metabolism 56:380-387 (Pubitemid 46217803)